A 51-year-old woman with shortness of breath and edema

Arthritis Care and Research

Volumn 59, Issue 8, 2008, Pages 1184-1190

  Desai, Sonali ^a,c   Clement, Jessica ^b   Landaw, Stephen ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c PBB B3 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; METOPROLOL; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACUTE KIDNEY FAILURE; ADD ON THERAPY; ADULT; ANEMIA; ARTHRALGIA; ARTICLE; CASE REPORT; CREATININE BLOOD LEVEL; DRUG DOSE TITRATION; DYSPNEA; EMERGENCY CARE; FEMALE; HEMODIALYSIS; HUMAN; HUMAN TISSUE; HYPERTENSION; JOINT STIFFNESS; KIDNEY FAILURE; LEG EDEMA; LUNG CONGESTION; MORPHEA; OPTIMAL DRUG DOSE; PERITONEAL DIALYSIS; PLASMAPHERESIS; PLEURA EFFUSION; SCLERODERMA; TACHYCARDIA; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE;

DIAGNOSIS, DIFFERENTIAL; DYSPNEA; EDEMA; FEMALE; HUMANS; HYPERTENSION, MALIGNANT; KIDNEY DISEASES; MIDDLE AGED; PURPURA, THROMBOTIC THROMBOCYTOPENIC; SCLERODERMA, SYSTEMIC;

EID: 49549112041     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23934     Document Type: Article

References (25)

1. George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000;96:1223-9.
2. Steen VD, Medsger TA Jr, Osial TA Jr, Ziegler GL, Shapiro AP, Rodnan GP. Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 1984;76:779-86.
3. Petri M. Pathogenesis and treatment of the antiphospholipid antibody syndrome. Med Clin North Am 1997;81:151-77.
4. Brain MC. Microangiopathic hemolytic anemia. N Engl J Med 1969;281:833-5.
5. Nesher G, Hanna VE, Moore TL, Hersh M, Osborn TG. Thrombotic microangiographic hemolytic anemia in systemic lupus erythematosus. Semin Arthritis Rheum 1994;24:165-72.
6. Vesely SK, George JN, Lammle B, Studt JD, Alberio L, El-Harake MA, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003;102:60-8.
7. Stave GM, Croker BP. Thrombotic microangiopathy in antiglomerular basement membrane glomerulonephritis. Arch Pathol Lab Med 1984;108:747-51.
8. Ross CN, Reuter H, Scott D, Hamilton DV. Microangiopathic haemolytic anaemia and systemic vasculitis. Br J Rheumatol 1996;35:377-9.
9. Hamasaki K, Mimura T, Kanda H, Kubo K, Setoguchi K, Satoh T, et al. Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: a case report and literature review. Clin Rheumatol 2003;22:355-8.
10. Musio F, Bohen EM, Yuan CM, Welch PG. Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus. Semin Arthritis Rheum 1998;28:1-19.
11. Asherson RA, Cervera R, Piette JC, Font J, Lie JT, Burcoglu A, et al. Catastrophic antiphospholipid syndrome: clinical and laboratory features of 50 patients. Medicine (Baltimore) 1998;77:195-207.
12. Espinosa G, Bucciarelli S, Cervera R, Lozano M, Reverter JC, de la Red G, et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis 2004;63:730-6.
13. Steen VD. Scleroderma renal crisis. Rheum Dis Clin North Am 2003;29:315-33.
14. Lammle B, Kremer Hovinga JA, Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemost 2005;3:1663-75.
15. Manadan AM, Harris C, Block JA. Thrombotic thrombocytopenic purpura in the setting of systemic sclerosis. Semin Arthritis Rheum 2005;34:683-8.
16. Liu L, Choi H, Bernardo A, Bergeron AL, Nolasco L, Ruan C, et al. Platelet-derived VWF-cleaving metalloprotease AD-AMTS-13. J Thromb Haemost 2005;3:2536-44.
17. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001;413:488-94.
18. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, et al, and the Canadian Apheresis Study Group. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991;325:393-7.
19. Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2007;66:754-63.
20. Moore HC, Sheehan HL. The kidney of scleroderma. Lancet 1952;1:68-70.
21. Teixeira L, Mahr A, Berezne A, Noel LH, Guillevin L, Mouthon L. Scleroderma renal crisis, still a life-threatening complication. Ann N Y Acad Sci 2007;1108:249-58.
22. Pham PT, Pham PC, Danovitch GM, Gritsch HA, Singer J, Wallace WD, et al. Predictors and risk factors for recurrent scleroderma renal crisis in the kidney allograft: case report and review of the literature. Am J Transplant 2005;5:2565-9.
23. Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998;41:1613-9.
24. Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990;113:352-7.
25. Santiago M, Baron M, Hudson M, Burlingame RW, Fritzler MJ. Antibodies to RNA polymerase III in systemic sclerosis detected by ELISA. J Rheumatol 2007;34:1528-34.